Indication for and Impact of Switching from Pirfenidone to Nintedanib in Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Hogben, C. [1 ]
Kouranos, V. [2 ]
Kokosi, M. [3 ]
Renzoni, E. A. [4 ]
Chua, F. [5 ]
Wells, A. U. [6 ]
Maher, T. M. [3 ]
Molyneaux, P. L. [5 ]
George, P. M. [7 ]
机构：
[1] Royal Brompton & Harefield NHS Fdn Trust, Interstitial Lung Dis Unit, London, England
[2] Royal Brompton Hosp, Interstitial Lung Dis, London, England
[3] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[4] Imperial Coll, Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
[5] Royal Brompton & Harefield NHS Fdn Trust, London, England
[6] Royal Brompton Hosp, Resp, London, England
[7] Royal Brompton Hosp, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1635
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis: current and future perspectives.
    Leonardo Galindo, Javier
    Andres Celis, Carlos
    Mejia, Mayra
    INVESTIGACION CLINICA, 2018, 59 (04): : 369 - 385
  • [32] Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
    Takehara, Kazutaka
    Koga, Yasuhiko
    Hachisu, Yoshimasa
    Utsugi, Mitsuyoshi
    Sawada, Yuri
    Saito, Yasuyuki
    Yoshimi, Seishi
    Yatomi, Masakiyo
    Shin, Yuki
    Wakamatsu, Ikuo
    Umetsu, Kazue
    Kouno, Shunichi
    Nakagawa, Junichi
    Sunaga, Noriaki
    Maeno, Toshitaka
    Hisada, Takeshi
    CELLS, 2022, 11 (01)
  • [33] Forced Vital Capacity in Idiopathic Pulmonary Fibrosis - FDA Review of Pirfenidone and Nintedanib
    Karimi-Shah, Banu A.
    Chowdhury, Badrul A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (13): : 1189 - 1191
  • [34] Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
    Huh, Jin-Young
    Lee, Jae Ha
    Song, Jin Woo
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [35] Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report
    Hagmeyer, Lars
    Treml, Marcel
    Priegnitz, Christina
    Randerath, Winfried J.
    RESPIRATION, 2016, 91 (04) : 327 - 332
  • [36] Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
    Huh, Jin-Young
    Lee, Jae Ha
    Song, Jin Woo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [37] Safety of Combined Pirfenidone and Nintedanib in Subgroups of Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Flaherty, K.
    Fell, C. D.
    Huggins, J. T.
    Nunes, H.
    Sussman, R.
    Valenzuela, C.
    Petzinger, U.
    Stauffer, J. L.
    Gilberg, F.
    Bengus, M.
    Wijsenbeek, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [38] COST EFFECTIVENESS OF NINTEDANIB VERSUS PIRFENIDONE TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS IN TURKEY
    Demir, O.
    Tetik, E.
    Kamaci, E.
    Cheynel, J.
    VALUE IN HEALTH, 2017, 20 (09) : A646 - A646
  • [39] A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review
    Man, Ruzhual K.
    Gogikar, Amaresh
    Nanda, Ankita
    Janga, Lakshmi Sai Niharika
    Sambe, Hembashima G.
    Yasir, Mohamed
    Ramphall, Shivana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [40] Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
    Chianese, Maria
    Screm, Gianluca
    Salton, Francesco
    Confalonieri, Paola
    Trotta, Liliana
    Barbieri, Mariangela
    Ruggero, Luca
    Mari, Marco
    Reccardini, Nicolo
    Geri, Pietro
    Hughes, Michael
    Lerda, Selene
    Confalonieri, Marco
    Mondini, Lucrezia
    Ruaro, Barbara
    PHARMACEUTICALS, 2024, 17 (06)
12345